Obesity
Page 1 • 4 itemsGain critical insights into global obesity drug development, market trends, and regulatory landscapes. Drive your pharma strategy with NovaPharmaNews intelligence.
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
Viking Therapeutics VK2735 Phase 3 Obesity Trials Fully Enrolled as Company Reports Q1 2026 Results
Viking Therapeutics advances VK2735 obesity treatment with fully enrolled Phase 3 trials and $603M cash position, oral formulation trial expected Q4 2026.
FormBlends Releases 2026 Peptide Report as RFK-Era HHS Reshapes GLP-1 Therapy Access
FormBlends' 2026 State of Peptides report analyzes how RFK Jr.'s HHS and new obesity drugs from major pharma are changing GLP-1 therapy access for Americans.
Corbus Pharmaceuticals CRB-913 Obesity Drug Completes Patient Enrollment in CANYON-1 Phase 1b Trial
Corbus Pharmaceuticals completes enrollment for CRB-913 obesity treatment Phase 1b trial, targeting summer 2026 results with 240 patients enrolled.